These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 7545340)

  • 21. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
    Barry MJ; Mulley AJ
    J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
    [No Abstract]   [Full Text] [Related]  

  • 22. Early detection of prostate cancer. Role of prostate-specific antigen.
    Prabhakaran VM
    Can Fam Physician; 1996 Apr; 42():709-12. PubMed ID: 8653039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Re: Prostate-specific antigen: a misused and maligned prostate cancer biomarker.
    Hamilton RJ; Platz EA; Freedland SJ
    J Natl Cancer Inst; 2009 Apr; 101(8):611-2. PubMed ID: 19351913
    [No Abstract]   [Full Text] [Related]  

  • 24. [PSA based screening for prostatic cancer].
    Johansen TE
    Tidsskr Nor Laegeforen; 2008 Nov; 128(22):2612-4. PubMed ID: 19023357
    [No Abstract]   [Full Text] [Related]  

  • 25. Screening for prostate cancer.
    Ruffin MT
    J Fam Pract; 1999 Aug; 48(8):581-2. PubMed ID: 10496634
    [No Abstract]   [Full Text] [Related]  

  • 26. Prostate-cancer screening.
    Cooperberg MR; Carroll PR
    N Engl J Med; 2009 Jul; 361(2):203; author reply 204-5. PubMed ID: 19593852
    [No Abstract]   [Full Text] [Related]  

  • 27. [Examination of serum prostate specific antigen (PSA) in the mass screening for prostatic diseases].
    Kato M; Okada K
    Hinyokika Kiyo; 1993 Mar; 39(3):221-3. PubMed ID: 7685140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate cancer and free PSA in routine laboratory use.
    Collins GN; O'Reilly PH; Brooman PJ; Earnshaw RJ; Martin PJ
    Br J Urol; 1997 Dec; 80(6):971-2. PubMed ID: 9439435
    [No Abstract]   [Full Text] [Related]  

  • 29. Prostate-cancer screening.
    Catalona WJ
    N Engl J Med; 2009 Jul; 361(2):202; author reply 204-5. PubMed ID: 19587348
    [No Abstract]   [Full Text] [Related]  

  • 30. Re: Is a screening interval of every 4 years for prostate cancer acceptable?
    Roobol MJ; Schröder FH
    J Natl Cancer Inst; 2008 Feb; 100(3):222; author reply 223-4. PubMed ID: 18230797
    [No Abstract]   [Full Text] [Related]  

  • 31. Commentary: how serious is getting a diagnosis of prostate cancer?
    Barry MJ
    Oncologist; 2008 Mar; 13(3):306-8. PubMed ID: 18378541
    [No Abstract]   [Full Text] [Related]  

  • 32. [Screening for prostate cancer: results from the first screening round in the French population of the ERSPC trial].
    Richard F
    Prog Urol; 2009 Jul; 19(7):499-500. PubMed ID: 19559381
    [No Abstract]   [Full Text] [Related]  

  • 33. Prostate-specific antigen and screening for prostate cancer.
    Han M; Gann PH; Catalona WJ
    Med Clin North Am; 2004 Mar; 88(2):245-65, ix. PubMed ID: 15049577
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate specific antigen: a useful screening test?
    Concato J
    Cancer J; 2000 Apr; 6 Suppl 2():S188-92. PubMed ID: 10803835
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Usefulness of free prostate specific antigen in the detection of prostate cancer].
    Azócar G; Castillo O; Van Cauwelaert R; Cumsille MA; Campero JM; Aguirre C; Wöhler C
    Rev Med Chil; 1999 Feb; 127(2):151-7. PubMed ID: 10436694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Screening for prostatic cancer].
    Pushkar' DIu; Govorov AV; Bormotin AV
    Urologiia; 2003; (1):10-5. PubMed ID: 12621959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What to do with an abnormal PSA test.
    Loeb S; Catalona WJ
    Oncologist; 2008 Mar; 13(3):299-305. PubMed ID: 18378540
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate-cancer screening.
    Dubben HH
    N Engl J Med; 2009 Jul; 361(2):204; author reply 204-6. PubMed ID: 19593854
    [No Abstract]   [Full Text] [Related]  

  • 39. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
    Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
    Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The jury is still out with regard to screening for the prostate cancer with prostate-specific antigen.
    Eur J Cancer Care (Engl); 2002 Jun; 11(2):78. PubMed ID: 12168606
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.